GSK Partners with Canadian Biotech Medicago on COVID-19 Vaccine

GlaxoSmithKline (GSK) has teamed up with Canadian biotech company Medicago to develop a COVID-19 vaccine.

The companies plan to launch a phase 1 clinical trial of the vaccine this month.

Medicago will contribute virus-like particles (VLPs) produced through recombinant DNA technology that stimulate an immune response to the coronavirus, and GSK will supply an  adjuvant to boost the response.